Melanoma & Skin Cancer

Hussein A. Tawbi, MD, PhD, discusses the efficacy of relatlimab plus nivolumab in patients with advanced melanoma.

The addition of lifileucel to pembrolizumab resulted in an overall response rate of 85.7% compared with pembrolizumab alone in patients with immune checkpoint inhibitor–naïve advanced melanoma.

The anti–PD-L1, fully human monoclonal antibody cosibelimab will be examined in a cohort of patients with metastatic cutaneous squamous cell carcinoma as part of an ongoing phase 1 study.

Due to its rarity, there will likely never be a television advertisement for Merkel cell carcinoma. Yet, several opportunities to help raise awareness and conduct an array of clinical trials are building, due to the disease’s response to checkpoint blockade.

The safety and efficacy of the combination of vidutolimod and nivolumab is currently under investigation in patients with PD-1–refractory advanced melanoma.

Dr. Baumann sheds light on the incidence, prognosis, and treatment of patients with Merkel cell carcinoma, ongoing clinical research, and strategies to raise awareness for this rare disease.

Merkel cell carcinoma is a rare, highly aggressive skin tumor associated with the Merkel cell polyomavirus infection, which has been detected in nearly 80% of MCC diagnoses.

James A. DeCaprio, MD, discusses raising awareness in Merkel cell carcinoma.

Sandra P. D’Angelo, MD, discusses the incidence and prognosis of patients with Merkel cell carcinoma.

Drs Park, Daniels, Sanghvi, and Kolb, discuss two high-risk non-melanoma skin cancer cases and highlighted patient and tumor risk factors to consider in the clinical setting.

Douglas B. Johnson, MD, discusses the rationale for examining chronic immune-related adverse effects associated with anti–PD-1 therapy in patients with high-risk resected melanoma.

The addition of relatlimab to nivolumab more than doubled the median progression-free survival compared with nivolumab alone in patients with previously untreated, unresectable or metastatic melanoma.

Tumor-infiltrating lymphocytes, a neoantigen-targeting therapy, has been shown to be a potentially curative treatment for patients with metastatic melanoma, and has led to clinical responses in this population even after failure with checkpoint inhibitors

Suthee Rapisuwon, MD, discusses clinical trial barriers for patients with mucosal melanoma in the United States.

Dr. Sezar and Dr. Stratigos discuss the FDA approvals of cemiplimab-rwlc in advanced non–small cell lung cancer and advanced basal cell carcinoma.

Michael A. Davies, MD, PhD, discusses the potential utility of ERK inhibitors in melanoma.

Suthee Rapisuwon, MD, discusses the potential utility of toripalimab in melanoma subtypes.

Arsen Osipov, MD, discusses the role of combination immunotherapy across multiple tumor types.

Michael A. Davies, MD, PhD, discusses the management of patients with melanoma during the COVID-19 pandemic.

Suthee Rapisuwon, MD, discusses the utility of frontline immunotherapy vs targeted therapy in acral and mucosal melanoma.

The FDA has granted an Orphan Drug designation to the investigational tumor-infiltrating lymphocyte therapy ITIL-168 for the treatment of patients with stage IIB to IV melanoma.

The first patient with PD-1/PD-L1–refractory melanoma has been dosed in the phase 2 LUMINOS-102 trial, which will evaluate the safety and efficacy of PVSRIPO alone or in combination with a PD-1/PD-L1 inhibitor in this patient population.

Suthee Rapisuwon, MD, discusses the biologic differences between mucosal and cutaneous melanoma.

Darovasertib, both as a single agent and in combination with binimetinib, has demonstrated promising early activity in patients with metastatic uveal melanoma, according to preliminary data from an ongoing phase 1/2 trial.

Although anticancer therapies that leverage T cells have commanded the most attention in the immuno-oncology era of the past decade, strategies based on natural killer cells have recently emerged as attractive approaches.